Clinical trial · Observational
Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC
NCT07500259CI-TRIAL-00115501COLOPanrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids/organoids.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| PDAC - Pancreatic Ductal Adenocarcinoma | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Personalized Functional Profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CRC
- description
- Participants are included while scheduled for biopsy or surgery of their colorectal cancer.
- interventionNames
- Other: Personalized Functional Profiling
- label
- PDAC
- description
- Participants are included while scheduled for biopsy or surgery of their cancer.
- interventionNames
- Other: Personalized Functional Profiling
Primary outcomes (1)
- measure
- PFP platform's predictive performance
- timeFrame
- 0-5 years
- description
- Degree of concordance between drug sensitivity profiles generated by the PFP platform and actual clinical responses observed in patients with CRC and PDAC treated with Standard of Care therapies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent form * ≥ 18 years of age * Willing and able to comply with the protocol for the duration of the study, including data and sample collection * Patient scheduled for surgery or biopsy (primary tumour or metastasis) PDAC Exclusion Criteria: * Female patient, pregnant, planning a pregnancy or breastfeeding. * Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * Patient unable to understand and provide informed consent and has no family member representing him/her. * Patients with any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise the patient's safety.
References
Publications (0)
Data not yet available
No reference posted for this study.